| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5702511 | Urologic Oncology: Seminars and Original Investigations | 2017 | 7 Pages |
Abstract
LNI and/or LN progression is a rare entity in patients with localized RCC. Nonetheless, patients with larger tumors might still benefit from LND because of a non-negligible risk of LNI and/or LN progression.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Paolo M.D., Alessandro M.D., Fabio M.D., Ettore M.D., Francesco M.D., Francesco M.D., Cristina Carenzi, Alberto M.D., Andrea M.D., Francesco M.D., Roberto M.D., Umberto M.D.,